Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine whether the MEL 80 Excimer Laser is effective in the treatment of moderate to high myopia (nearsightedness), when used as part of the Laser In Situ Keratomileusis (LASIK) procedure.
LASIK has become one of the most common refractive eye procedures performed in the country. Currently the MEL 80 Excimer Laser System is approved for the elimination of myopia of less than or equal to -7.0 D with or without refractive astigmatism of less than or equal to -3.0 D, with a maximum MRSE of -7.00 D. The goal of this study is to assess the safety and effectiveness information on the treatment of moderate to high magnitudes of myopia.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MEL 80 Treatment of High Myopia | Device | The reduction or elimination of myopia > -7.00 D to -12.00 D, and astigmatism less than or equal to -6.00 D at the spectacle plane (myopia with or without astigmatism), with a maximum MRSE ≤ -12.00 D. |
| Measure | Description | Time Frame |
|---|---|---|
| At the point of stability, for myopes > 7 D spherical equivalent (SE), a minimum of 30% should have an achieved refraction within ± 0.50 D of the intended outcome, and 60% should have an achieved refraction within ± 1.00 D of the intended outcome. | Point of stability | |
| For myopes > 7 D spherical equivalent (SE), a minimum of 75% of eyes should have an uncorrected visual acuity of 20/40 or better at the postoperative interval at which stability has been established. | Point of stability | |
| 95% of eyes should have a change of < 1.00 D in manifest refraction spherical equivalent (MRSE) between 2 refractions performed at least 3 months apart, and the mean rate of MRSE change per month should be < 0.04 D. | Point of stability | |
| Distance BSCVA of worse than 20/40 at the postoperative interval at which stability has been established should occur in less than 1% of eyes that had a BSCVA of 20/20 or better before surgery. | Point of stability | |
| Loss of more than 2 lines of BSCVA should occur in less than 5% of eyes | Point of stability | |
| Less than 5% of eyes treated for sphere only should have a magnitude of postoperative manifest refractive astigmatism that varies from baseline cylinder by greater than 2.00 D at the postoperative interval at which stability has been established. | Point of stability | |
| Incidence of Adverse Events to occur in less than 1% of eyes | Postopertive visits |
| Measure | Description | Time Frame |
|---|---|---|
| Subject Satisfaction: As measured by a subjective questionnaire, and will be considered as a secondary efficacy variable. | Postoperative visits 3, 6, 9 and 12 months | |
| Incidence of Complications | Postoperative visits |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| John Doane, MD | Discover Vision Centers | Principal Investigator |
| Richard Hoffman, MD | Fine, Hoffman, and Packer LLC | Principal Investigator |
| Howard Fine, MD | Fine, Hoffman, and Packer LLC | Principal Investigator |
| Mark Packer, MD | FIne, Hoffman, and Packer LLC | Principal Investigator |
| David Tanzer, MD | US Navy Refractive Surgery Center, San Diego, CA | Principal Investigator |
| John Vukich, MD | Davis Duehr Dean Eye Clinic | Principal Investigator |
| Jon Dishler, MD | Dishler Laser Institute | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| US Navy Refractive Surgery Center | San Diego | California | 92106 | United States | ||
| Dishler Laser Institute |
Not provided
| ID | Term |
|---|---|
| D009216 | Myopia |
| ID | Term |
|---|---|
| D012030 | Refractive Errors |
| D005128 | Eye Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Patient Symptoms: As measured by a subjective questionnaire, will be considered as a secondary safety variable | Preoperative and Postoperative visits 3, 6, 9 and 12 months |
| Greenwood Village |
| Colorado |
| 80111 |
| United States |
| Discover Vision Centers | Kansas City | Missouri | 64055 | United States |
| Fine, Hoffman, and Packer | Eugene | Oregon | 97401 | United States |
| Davis Duehr Dean Eye Clinic | Madison | Wisconsin | 53717 | United States |